Arbutus Biopharma (ABUS) vs Alto Neuroscience (ANRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alto Neuroscience (ANRO) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 296.0% versus a gain of 0.0%. Alto Neuroscience is the larger company by market cap ($923.0 million vs $657.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | ANRO |
|---|---|---|
| Share price | $4.29 | $23.52 |
| Market cap | $657.55M | $922.97M |
| 1-day change | -4.24% | -0.72% |
| YTD return | -10.81% | +32.13% |
| 1-year return | 0.00% | +295.96% |
| 5-year return | +5.15% | — |
| P/E ratio (TTM) | 5.43 | — |
| EPS (TTM) | $0.79 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $37.48 |
| 52-week low | $3.50 | $5.23 |
| Distance from 52-week high | -21.28% | -37.25% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +24.71% | +63.18% |
| Average volume | 4.68M | 543.14K |
| Shares outstanding | 153.28M | 39.24M |
| Employees | 19 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANRO has outperformed ABUS by 296.0 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
ABUS vs ANRO FAQ
Which is bigger, Arbutus Biopharma or Alto Neuroscience?
Alto Neuroscience (ANRO) is larger, with a market capitalization of $922.97M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or ANRO?
ANRO returned +295.96% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Alto Neuroscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.